We are live on ! Find out more

Kodiak Sciences

KOD

Market cap $2.08B

33.14 USD

+0.25

0.76%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

33.60

+0.46

1.39%

1 day

0.76%

5 days

-4.52%

1 month

-19.85%

3 months

-2.7%

6 months

42.17%

Year to date

27.36%

1 year

254.44%

5 years

-64.71%

10 years

226.18%

About: Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Employees: 124

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 57.1%

Negative 0%

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Zacks Investment Research

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

Zacks Investment Research

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME).

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027 PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation ("MESI").

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Zacks Investment Research

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Zacks Investment Research

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

See News Rankings

Price charts implemented using Lightweight Charts™